SAN FRANCISCO, July 15 — The race to tame one of cancer’s most stubborn molecular targets is heating up. Erasca, a California-based biotechnology company, is among a crowded field of drug developers all aiming at the RAS/MAPK pathway — a cellular signaling network that, when mutated, drives many of the hardest-to-treat cancers. The company is taking a distinct approach: focusing on pan-RAS inhibitors and combination strategies designed to outsmart the resistance mechanisms that so often defeat existing therapies.
The field already has two FDA-approved drugs targeting the specific KRAS G12C mutation. Amgen’s sotorasib, sold as Lumakras, became the first such inhibitor to win US approval in May 2021 for non-small cell lung cancer.
Mirati Therapeutics followed with adagrasib (Krazati), which received its own FDA green light in December 2022 for the same indication. Mirati was later acquired by Bristol Myers Squibb in October 2023 for $5.8 billion, a deal that underscored the immense commercial promise of this class of medicines.
A crowded field, a common goal
Beyond the approved drugs, the pipeline is deep. Revolution Medicines is developing RMC-4630, a SHP2 inhibitor, and RMC-6291, a RAS(ON) inhibitor. BridgeBio Pharma is working on BBP-398, another SHP2 inhibitor.
Wellcome Trust-backed MRC Technology also has programs in the space. What sets Erasca apart, according to the company’s public positioning, is its deliberate focus on pan-RAS inhibitors — therapies that could potentially hit multiple RAS mutations at once, rather than just one — and on combining those agents to block the escape routes cancer cells use to survive treatment.
Resistance is the central challenge in this field; tumors that initially shrink on a KRAS G12C inhibitor often find a way to grow back. The global market for RAS-targeted therapies is projected to reach $15 billion by 2030, according to market research firm Evaluate Pharma — a figure that signals both the scale of unmet need and the intensity of the commercial race.
What it means for patients
The RAS family of genes were long considered “undruggable.” The arrival of sotorasib and adagrasib changed that narrative, proving that targeted therapy against KRAS G12C could work. But those drugs only help patients whose tumors carry that specific mutation. A pan-RAS approach, if successful, could broaden the number of patients who might benefit.
Erasca’s strategy of combining inhibitors to tackle resistance is also drawing attention. In cancer treatment, single-agent therapies often buy time, but combination regimens have a better shot at durable responses.
The company has not yet disclosed late-stage clinical data for its lead programs, but the field is watching closely. The competition is fierce, but for the scientists and the families waiting, progress is what matters. The next few years will determine which approaches deliver real-world results. Consult your doctor for medical advice.
